Back to Agenda
European Regulatory Town Hall Meeting: EMA Relocation and Implication for Centralised Activities
Session Chair(s)
Melanie Carr
Head of Stakeholders and Communication Division
European Medicines Agency, Netherlands
The European Regulatory Town Hall will provide an opportunity to update on recent developments and future direction of the EMA, the European Commission and the EU regulatory network, with specific focus on the relocation of the EMA and the business continuity plans that are in place.
Come listen to the latest issues from a panel consisting of senior leadership from the EMA and National Competent Authorities.
- Update on timelines for EMA’s relocation and next steps
- Business continuity plans and measures being taken to address stakeholders needs
- Spotlight on EMA’s priorities to 2020
- Update from the European Commission on the state of play and next steps
- Work ongoing to prepare for Brexit from CHMPs perspective
- Response of the European Medicines Regulatory Network to prepare for Brexit
- Stakeholders expectations for Brexit and beyond
Speaker(s)
Panel Discussion
Nicola Bedlington
European Patient's Forum, Belgium
Special Advisor
Panel Discussion
Tomas Salmonson, DrMed, PhD
Critical Path Institute, United States
Partner
Panel Discussion
Nathalie Moll
European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium
Director General
Panel Discussion
Csilla Pozsgay
National Institute of Pharmacy and Nutrition, Hungary
Director General
Panel Discussion
Guido Rasi, MD
Tor Vergata University of Rome, Italy
Chairman,Clinical Trial Center of Gemelli Polyclinic Inst; Prof of Microbiology
Have an account?